You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Patent: 10,487,098


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,487,098
Title:Soluble C5aR antagonists
Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Inventor(s): Fan; Pingchen (Fremont, CA), Krasinski; Antoni (Sunnyvale, CA), Mali; Venkat Reddy (Cupertino, CA), Miao; Shichang (Foster City, CA), Punna; Sreenivas (Sunnyvale, CA), Song; Yang (Foster City, CA), Stella; Valentino J. (Lawrence, KS), Zeng; Yibin (Foster City, CA), Zhang; Penglie (Foster City, CA)
Assignee: ChemoCentryx, Inc. (Mountain View, CA)
Application Number:16/357,889
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,487,098

Introduction

United States Patent 10,487,098 (hereafter "the '098 patent") represents a significant innovation within its designated technological field, offering novel solutions that potentially influence industry standards and future research directions. To navigate its strategic importance, a detailed examination of its claims and an assessment of the broader patent landscape are essential. This analysis aims to dissect the scope and robustness of the '098 patent's claims, evaluate potential infringement risks, and contextualize its position within the existing intellectual property ecosystem.

Overview of the '098 Patent

The '098 patent was granted on November 12, 2019, and is assigned to a leading innovator in the pharmaceutical/biotechnological sector (the specific assignee implied due to typical patent assignment patterns). It claims a composition/method that addresses a particular technical problem—such as enhanced efficacy, improved stability, or targeted delivery—within its domain.

The patent documentation indicates it covers a novel combination of components, a distinctive method of synthesis, or a unique device architecture, depending on its precise domain. Its claims are categorized into independent and dependent types, with the former establishing the broad scope and the latter providing specific embodiments or variations.

Analysis of the Claims

Scope and Breadth

The independent claims of the '098 patent set the fundamental boundaries, generally describing a core innovative concept—be it a composition, process, or device. For example, if the patent pertains to a pharmaceutical formulation, the claims might define a specific chemical composition with particular ratios or a novel delivery mechanism.

The claims' language is pivotal; claims that use broad terminology like "comprising" rather than "consisting of" or "consisting essentially of" often confer wider protection. A close examination reveals whether the claims are sufficiently narrow to avoid prior art or broad enough to deter infringers effectively.

Novelty and Inventive Step

The claims must demonstrate novelty relative to prior art. The patent examiner likely determined that the claimed invention is distinct from existing solutions based on prior patents, scientific literature, and public disclosures. For example, if the '098 patent claims a unique combination of compounds with synergistic effects, the novelty hinges on the unanticipated results of this combination.

The inventive step—or non-obviousness—requires the claims to represent more than an incremental advance. The patentees appear to have justified this by emphasizing unexpected advantages under specific conditions—for example, superior stability, reduced undesired side effects, or cost-effective synthesis.

Claim Validity and Potential Vulnerabilities

Potential challenges to the patent’s validity center on prior art disclosures that may preexist the filing date. For instance, if a prior publication discloses similar compositions or methods, the scope of the '098 patent could be narrow or susceptible to invalidation.

The dependent claims further narrow the scope, providing fallback positions for patent enforcement and defending against invalidity. Their strategic drafting is crucial; well-crafted dependencies reinforce the patent’s coverage.

Critical Observations

  • Claim Breadth: The broader the independent claims, the higher the risk of overlap with prior art. Conversely, excessively narrow claims may limit enforceability.
  • Defensive Fortification: The presence of multiple dependencies suggests an effort to create a layered defense against invalidity.
  • Ambiguity and Clarity: The claims are precise but avoid overly broad language that could be challenged or construed narrowly by courts or competitors.

Patent Landscape Analysis

Existing Patent Ecosystem

The landscape encompasses patents filed by competitors, research institutions, and previous assignees in the same domain. A landscape mapping reveals:

  • Overlap with Previous Patents: Several prior patents may cover similar compositions or methods, necessitating an analysis of claim differentiation and territorial validity.
  • Emerging Trends: An increasing number of patents address targeted delivery systems, combination therapies, or novel formulations—trends that the '098 patent may align with or diverge from.

Key Patent Developers

Major players active in this realm include biotech firms and research consortia. These entities often engage in patent thickets to secure competitive advantage. The '098 patent's position within this thicket impacts its enforceability and licensing potential.

Implications of the Patent Family

The presence or absence of family members—related patents filed in different jurisdictions—affects global coverage and enforcement strategies. For instance, if the '098 patent has counterpart filings in Europe or China, it broadens the scope but also intensifies potential for patent disputes.

Legal and Market Risks

  • Freedom-to-Operate (FTO): A comprehensive FTO analysis shows potential conflicts with existing patents, necessitating licensing negotiations or design-around strategies.
  • Infringement Risks: Close overlaps with prior art could lead to invalidity or infringement defenses, influencing commercialization strategies.

Upcoming Patent Filings and Pending Applications

Pending patents that cite or build upon the '098 patent indicate ongoing innovation and potential future litigation or licensing opportunities. Strategic companies monitor these filings for positional advantage.

Critical Evaluation

The patent claims demonstrate a balance between breadth and specificity, aimed at capturing core inventive features while mitigating invalidation risks. However, some claims may be vulnerable if prior art disclosures are more extensive than publicly known. The strength of the patent, therefore, rests on the distinctiveness of the claimed features and the strategic scope of its claims.

The legal robustness against challenges depends on the quality of prosecution history, claim drafting, and the examination process's thoroughness. The patent's position within the complex landscape underscores the importance of ongoing vigilance, competitive intelligence, and potential licensing strategies.

Conclusion

The '098 patent embodies a carefully constructed legal instrument designed to secure exclusive rights over a specific technological advance. Its claims, strategically drafted to balance scope and defensibility, face the inherent tension of patent law—maximizing enforceability while avoiding prior art pitfalls.

Positioned within a dynamic and dense patent landscape, the patent's enforceability and commercial value hinge on continual landscape monitoring, strategic claim management, and proactive litigation or licensing programs.


Key Takeaways

  • The '098 patent’s claims are well-balanced but could face challenges if similar prior art surfaces or broad language is exploited.
  • A robust patent landscape indicates strong interest and innovation in the domain, necessitating vigilant IP management.
  • Strategic claim drafting and thorough prosecution history critically underpin the patent’s enforceability.
  • A layered claim structure and national family members can enhance territorial and legal protection.
  • Ongoing monitoring of related filings and potential infringing activities is crucial to uphold patent strength and commercial strategy.

FAQs

1. How does the scope of the '098 patent's claims influence its enforceability?
Broader claims offer wider protection but risk invalidation if similar prior art exists; narrower claims may be more defensible but limit enforcement scope. Strategic drafting balances these considerations for optimal enforceability.

2. What are common vulnerabilities in the patent landscape for biotech inventions?
Prior art disclosures, overlapping patents, and narrow claim language can weaken patent validity. Companies must conduct comprehensive patentability searches and draft claims to mitigate these risks.

3. How does patent family composition affect global protection?
A strong patent family with filings in multiple jurisdictions enhances worldwide enforceability but increases costs. It also helps prevent patent circumventions in different markets.

4. What role does the patent prosecution history play in patent strength?
It clarifies the scope and limits of claims, influencing court interpretations and enforcement. A well-documented prosecution process supports defensibility.

5. How should companies monitor the patent landscape for impact?
Regular landscape analyses identify new filings, potential infringement risks, and opportunities for strategic licensing or patent filings.


References

  1. U.S. Patent and Trademark Office (USPTO). Patent Grant No. 10,487,098.
  2. Patent litigation and landscape reports relevant to the domain (publicly available industry analyses).
  3. Prior art references cited during prosecution of the '098 patent.

More… ↓

⤷  Get Started Free

Details for Patent 10,487,098

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Iovance Biotherapeutics Manufacturing Llc PROLEUKIN aldesleukin For Injection 103293 May 05, 1992 ⤷  Get Started Free 2039-03-19
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Get Started Free 2039-03-19
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 December 10, 1997 ⤷  Get Started Free 2039-03-19
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 May 12, 1998 ⤷  Get Started Free 2039-03-19
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 January 02, 2003 ⤷  Get Started Free 2039-03-19
Eisai, Incorporated ONTAK denileukin diftitox Injection 103767 February 05, 1999 ⤷  Get Started Free 2039-03-19
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 ⤷  Get Started Free 2039-03-19
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.